News | April 15, 2024
Croda and AAHI partner to drive innovation in vaccine development
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Subscribe To Our Newsletter & Stay Updated
